Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments. 

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development. 

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In